

September 12, 2016



Cryoport Provides Critical Assessment of the Impact of Packaging and Logistics Decisions on the CAR-T Clinical Pipeline

Systematic Study of the Impact of Logistics Decisions on the Integrity of Critical Biomarkers and Active Clinical Product and Data Generation

Impact of the Data on Clinical Progression in the CAR-T Space

IRVINE, Calif., Sept. 12, 2016 /PRNewswire/ --[Cryoport](http://cryoport.com), Inc. (NASDAQ: CYRX) ("Company"), the world's leading cryogenic logistics company, announced today that Dr. Mark Sawicki, Chief Commercial Officer, is scheduled to present at the 2nd Annual CAR & TCR Summit 2016 in Boston, as follows:

Date & Time: Wednesday, September 14 at 5:10 p.m.
Location: 2nd Annual CAR & TCR Summit 2016, Boston, MA
Booth: 11
Speakers: Dr. Mark Sawicki, Chief Commercial Officer, Cryoport
Jim Reiner, Senior Product Manager, UPS
Presentation Title: Critical Assessment of the Impact of Packaging and Logistics Decisions on the CAR-T Clinical Pipeline
Website: <http://car-tcr-summit.com/>

Dr. Mark Sawicki, Chief Commercial Officer, Cryoport and Jim Reiner, Senior Product Manager, UPS, will give a presentation on "Critical Assessment of the Impact of Packaging and Logistics Decisions on the CAR-T Clinical Pipeline". Scant peer reviewed research exists on the impact of logistics strategies including fulfillment, packaging, and transport on clinical sample, product, and data integrity, in particular in the management of regenerative therapies. In response, in conjunction with a number of our partners and clients, Cryoport has conducted a systematic study of the impact of logistics decisions on the integrity of critical biomarker and active clinical product and the subsequent data generation. This data will be discussed in relation to its impact on clinical progression in the CAR-T space, including:

- Determining the appropriate logistics strategy to ensure data integrity
- Supporting companies efforts to handle important cold chain shipping needs from Clinical Trials to Commercial Launch
- Meeting the distribution, transportation and regulatory requirements for product development and commercialization

"We are excited about the results of this study and are very enthusiastic about the utilization of this data in relation to its impact on logistics decisions when evaluating clinical progression in the CAR-T space. We appreciate the contributions of our partners and clients who participated in this study, and look forward to utilizing the study results to more effectively determine optimal transport conditions in supporting our clients efforts to handle important

biomarkers and CAR-T active clinical product from clinical trials to commercial launch," said Dr. Mark Sawicki, Chief Commercial Officer, Cryoport.

To request a meeting with Dr. Sawicki at the conference or for more information, please visit: <http://www.cryoport.com/car-tcr-summit>

About Cryoport, Inc.

Cryoport is the premier provider of cryogenic logistics solutions to the life sciences industry through its purpose-built proprietary packaging, information technology and specialized cold chain logistics expertise. The Company provides leading edge logistics solutions for biologic materials, such as immunotherapies, stem cells, CAR-T cells and reproductive cells for clients worldwide. Cryoport actively supports points-of-care, CRO's, central laboratories, pharmaceutical companies, contract manufacturers and university researchers. For more information, visit www.cryoport.com.

To download Cryoport's investor relations app, which offers access to SEC documents, press releases, videos, audiocasts and more, please click to download from your [iPhone and iPad](#) or [Android mobile device](#).

Forward Looking Statements

Statements in this news release which are not purely historical, including statements regarding Cryoport, Inc.'s intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic conditions, trends in the products markets, variations in the company's cash flow, market acceptance risks, and technical development risks. The company's business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended March 31, 2015. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Cryoport, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.



Logo - <https://photos.prnewswire.com/prnh/20160524/371732LOGO>

To view the original version on PR Newswire, visit <http://www.prnewswire.com/news-releases/cryoport-provides-critical-assessment-of-the-impact-of-packaging-and-logistics->

[decisions-on-the-car-t-clinical-pipeline-300325702.html](https://www.fda.gov/oc/decisions-on-the-car-t-clinical-pipeline-300325702.html)

SOURCE Cryoport, Inc.